Follow
Marc van der Valk
Marc van der Valk
Professor in medicine, university of Amsterdam
Verified email at amsterdamumc.nl
Title
Cited by
Cited by
Year
Future challenges for clinical care of an ageing population infected with HIV: a modelling study
M Smit, K Brinkman, S Geerlings, C Smit, K Thyagarajan, A van Sighem, ...
The Lancet infectious diseases 15 (7), 810-818, 2015
8882015
Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study
J Schouten, FW Wit, IG Stolte, NA Kootstra, M van der Valk, SE Geerlings, ...
Clinical Infectious Diseases 59 (12), 1787-1797, 2014
8672014
Mapping the human genetic architecture of COVID-19
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
7482021
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ...
Science immunology 6 (62), eabl4340, 2021
4702021
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals
A van Sighem, L Gras, P Reiss, K Brinkman, F de Wolf
Aids 24 (10), 1527-1535, 2010
4672010
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study
N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ...
European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010
4512010
X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19
T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ...
Science immunology 6 (62), eabl4348, 2021
3492021
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile
M van der Valk, JJP Kastelein, RL Murphy, F van Leth, C Katlama, ...
Aids 15 (18), 2407-2414, 2001
3272001
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
R Van Leeuwen, C Katlama, RL Murphy, K Squires, J Gatell, A Horban, ...
Aids 17 (7), 987-999, 2003
2672003
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial
MH van der Ree, JM de Vree, F Stelma, S Willemse, M van der Valk, ...
The Lancet 389 (10070), 709-717, 2017
2552017
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real …
TM Welzel, J Petersen, K Herzer, P Ferenci, M Gschwantler, ...
Gut 65 (11), 1861-1870, 2016
2382016
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
M Van der Valk, EH Gisolf, P Reiss, F Wit, A Japour, GJ Weverling, ...
Aids 15 (7), 847-855, 2001
2342001
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
AD Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, ...
The lancet Gastroenterology & hepatology 3 (2), 125-133, 2018
1672018
Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways
M van der Valk, PH Bisschop, JA Romijn, MT Ackermans, JMA Lange, ...
Aids 15 (16), 2093-2100, 2001
1532001
Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy
AJ Van der Kooi, G Bonne, B Eymard, D Duboc, B Talim, M Van der Valk, ...
Neurology 59 (4), 620-623, 2002
1492002
HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls
KW Kooij, FWNM Wit, J Schouten, M van der Valk, MH Godfried, IG Stolte, ...
Aids 30 (2), 241-250, 2016
1412016
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ...
Proceedings of the National Academy of Sciences 119 (21), 2022
1382022
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study
BE Nichols, CAB Boucher, M van der Valk, BJA Rijnders, ...
The Lancet Infectious Diseases 16 (12), 1423-1429, 2016
1282016
Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study
JW Vanhommerig, FAE Lambers, J Schinkel, RB Geskus, JE Arends, ...
Open forum infectious diseases 2 (3), ofv115, 2015
1212015
Transmission networks of HIV-1 among men having sex with men in the Netherlands
D Bezemer, A van Sighem, VV Lukashov, L van der Hoek, N Back, ...
Aids 24 (2), 271-282, 2010
1092010
The system can't perform the operation now. Try again later.
Articles 1–20